Anthrax vaccine adsorbed, adjuvanted - Biologic Drug Details

Summary for anthrax vaccine adsorbed, adjuvanted

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for anthrax vaccine adsorbed, adjuvanted

Ingredient-type	Anthrax Vaccines Vaccines, Attenuated
Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Live Attenuated Bacillus Anthracis Vaccine

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for anthrax vaccine adsorbed, adjuvanted Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for anthrax vaccine adsorbed, adjuvanted Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emergent Product Development Gaithersburg, Inc.	CYFENDUS	anthrax vaccine adsorbed, adjuvanted	Injection	125761	10,357,559	2034-12-23	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	CYFENDUS	anthrax vaccine adsorbed, adjuvanted	Injection	125761	10,456,463	2031-05-27	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	CYFENDUS	anthrax vaccine adsorbed, adjuvanted	Injection	125761	6,207,646	2016-10-30	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	CYFENDUS	anthrax vaccine adsorbed, adjuvanted	Injection	125761	6,406,705	2019-06-03	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	CYFENDUS	anthrax vaccine adsorbed, adjuvanted	Injection	125761	8,552,165	2029-12-08	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for anthrax vaccine adsorbed, adjuvanted Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for anthrax vaccine adsorbed, adjuvanted

Country	Patent Number	Estimated Expiration
Mexico	2011006088
Poland	2376107
Japan	2012511321
Spain	2683316
World Intellectual Property Organization (WIPO)	2010067262

Market Dynamics and Financial Trajectory for Anthrax Vaccine Adsorbed, Adjuvanted

Last updated: February 20, 2026

What is the Current Market for Anthrax Vaccines?

The global anthrax vaccine market is driven by biodefense needs, government contracts, and bioterrorism threat preparedness. The primary product, Anthrax Vaccine Adsorbed (AVA), has been in use since the 1970s for military and at-risk populations. The vaccine is authorized for prophylactic use in adults at high risk, primarily in the United States, with limited commercial applications elsewhere.

Estimated market size: approximately $200 million in 2022, expected to reach $250 million by 2027, at a CAGR of 4% [1].

How Do Market Drivers Impact the Financial Outlook?

• Government Procurement Programs: The U.S. Department of Defense (DoD) maintains a substantial stockpile, accounting for two-thirds of vaccine sales. Defense budgets support procurement, fostering revenue stability.

• Biodefense Funding: Increased investments in biothreat preparedness post-2010s, notably after biological threat assessments by agencies like CDC and DHS, sustain demand.

• Pandemic and Public Security Awareness: Heightened focus on biosecurity influences government expenditure, with contracts often awarded through competitive processes.

• Limited Commercial Market: Outside biodefense, civilian use remains minimal due to vaccine efficacy, safety profile, and regulatory hurdles for broader civilian markets.

What is the Financial Trajectory for Developing Next-Generation or Improved Products?

Innovations in adjuvants or formulation enhancements aim to:

• Reduce dosing schedules, decreasing manufacturing costs.
• Improve immune response, broadening use-case indications.
• Extend shelf life to facilitate stockpiling and logistics.

These advances may allow entry into civilian markets, creating new revenue streams. However, product development costs for novel adjuvants or formulations range from $50 million to $200 million, considering clinical trials, regulatory filings, and manufacturing scale-up [2].

Expected time to market: 5-8 years from R&D initiation.

Projected pricing: current AVA vaccines cost around $600 per dose; improved formulations could command premiums of 15-30%, depending on efficacy and safety profiles.

What Are the Key Financial Risks?

• Regulatory Delays: Changes in FDA policy or requirements can extend development timelines and increase costs.
• Market Saturation: Dependence on government stockpiling exposes revenue to political and budgetary fluctuations.
• Competitive Landscape: Entry of new biothreat vaccines or biodefense products from competitors could reduce market share.
• Public Perception and Acceptance: Vaccine hesitancy could impact procurement and stockpiling plans.

How Do Market and Financial Trends Compare to Historical Data?

Historical growth has been steady but slow. The market expanded from $100 million in 2007 to $200 million in 2022, driven mostly by government procurement. Predictions indicate moderate growth, constrained by the limited civilian application and reliance on government contracts. Solvent future prospects depend heavily on successful development and approval of advanced vaccine formulations.

Key Policy and Regulatory Considerations

• FDA Approval: AVA is licensed under the FDA's Biological License Application (BLA); new formulations require similar approval processes.

• Biodefense Funding Programs: U.S. projects such as Project BioShield support vaccine procurement, influencing market stability.

• International Market: Limited due to regulatory and logistical constraints, with some interest from allied nations, especially in Asia and Europe.

Investment Implications

Investors should focus on companies actively developing improved or next-generation anthrax vaccines. The financial potential exists if vaccine enhancements lead to broader civilian use or increased prophylactic efficacy that satisfies regulatory standards.

Summary Overview

Aspect	Details
Market Size (2022)	~$200 million
Projected Growth (2022-2027)	CAGR of 4%
Primary Revenue Source	U.S. Department of Defense procurement
Development Cost (new formulations)	$50 million to $200 million
Development Timeline	5-8 years
Pricing (current/formulated)	~$600 per dose; premium for advanced formulations

Key Takeaways

• The anthrax vaccine market remains niche, heavily driven by U.S. biodefense needs.
• Government procurement presents steady revenue but limits growth scope.
• Development of advanced formulations can expand use cases, but involves high costs and regulatory hurdles.
• Market risks include political changes, market saturation, and competitive pressures.
• Long-term growth depends on successful product innovation and potential civilian application.

Frequently Asked Questions

1. Who are the main competitors in anthrax vaccine development?
The primary current supplier is Emergent BioSolutions, with ongoing research from government agencies and biotech firms exploring improved formulations.

2. What regulatory challenges exist for new anthrax vaccine formulations?
New formulations must undergo FDA review, including safety and efficacy trials, a process that can take 5-8 years, with potential delays from regulatory feedback.

3. Are civilian applications of anthrax vaccines feasible?
Limited civilian use exists; expanding it requires demonstrating safety and efficacy beyond high-risk populations, with regulatory approval and market acceptance necessary.

4. How does biodefense funding affect vaccine market stability?
It provides consistent procurement volume, reducing revenue volatility for manufacturers reliant on government contracts.

5. Is there potential for international markets?
Yes, but limited by regulatory approval processes, logistical challenges, and local biodefense policies. Interest exists from select countries with strategic biosecurity programs.

---

References

[1] MarketWatch. (2022). Anthrax vaccine market size and forecast. Accessed from https://www.marketwatch.com

[2] Deloitte. (2020). Biotech product development costs: An industry overview. Accessed from https://www2.deloitte.com